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Table 1
Predictor b Standard Error p
Age 0,099 0,028 0,001
Telomere length -0,658 0,309 0,037
Fasting glucose 0,388 0,160 0,017
138 AbstractsHb1Ac 0,801 0,362 0,031Table 2
Predictor b Standard Error p
Age -0,026 0,010 0,015
HOMA-IR -0,176 0,056 0,027
Hb1Ac -0,213 0,148 0,155
Table 1
TL
Age rZ -0,2860
pZ 0,0003
Creatinine clearance (ml/min) rZ -0,4267
pZ 0,0167
MAU (mg/l) rZ -0,2718
pZ 0,0175
Urea (mmol/l) rZ -0,2521
pZ 0,0098
Table 2
PWV
Age rZ 0,5223
pZ 0,0001
TL rZ -0,2657
pZ 0,0096
Creatinine clearance (ml/min) rZ 0,1964
pZ 0,2814
MAU (mg/l) rZ 0,0186
pZ 0,8544
Urea (mmol/l) rZ 0,1784
pZ 0,0384In conclusion: TL along with indicators of glucose metabolism mainly deter-
mine arterial stiffness. There is a considerable impact of glucose regulation
on telomere dynamics. IR may be the main target in preventing accelerating
arterial aging.
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DIFFERENT EFFECTS OF 7-NITROINDAZOLE AND L-NAME ADMINISTERED
INDIVIDUALLY AND/OR TOGETHER ON CARDIOVASCULAR SYSTEM OF
ADULT WISTAR RATS
Kristek Frantisek, Malekova Magdalena, Cacanyiova Sona
Institute of Normal and Pathological Physiology, Centre of Excellence for
examination of regulatory role of nitric oxide, Bratislava, Slovakia
Objectives: We evaluate the effect of NG-nitro-L-arginine methylester (L-
NAME) and 7-nitroindazole (7NI) administered individually and/or together
on cardiovascular system of adult Wistar rats.
Methods: L-NAME (50 mg/kg/day in tap water) and 7NI (10 mg/kg/day in pel-
lets) was administered to Wistar rats from 10th-16th week of age. Blood pres-
sure (BP) was measured by the plethysmographic method weekly. For
morphological study the animals (nZ10 in each group) were perfused with
a fixative (120 mmHg) and carotid and coronary arteries were processed
for electron microscopy. For functional investigation aortal rings (nZ10 in
each group) in organ bath were used.
Results: L-NAME administration to Wistar rats evoked increase of BP, hyper-
trophy of the heart and arterial wall, increase of cross sectional areas (CSA)
of endothelial and muscle cells, increase of extracellular matrix, decrease of
endothelial dependent relaxation (EDR) to acetylcholine, and increase of
noradrenaline contraction. 7NI administration resulted in BP independent
hypotrophy of the heart and arterial wall, decrease CSA of endothelial and
muscle cells without affecting CSA of extracellular matrix, mild decrease
of acetylcholine induced EDR, and noradrenaline contraction. Common
administration of 7NI and L-NAME evoked (i) lower effect on BP, and trophic-
ity of both arteries and heart compared to L-NAME, and (ii), similar decrease
of EDR as in L-NAME group, and (iii) decreased contractile effect.
Conclusions: The results indicate that two different NO-synthase inhibitors
L-NAME and 7NI via decreased synthesis of the same NO molecule evoked
different and in many causes the opposite effects on cardiovascular system
of normotensive Wistar rats.
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SERUM UREA IS A NEW BIOMARKER OF CELLULAR AND VASCULAR AGING
V. Pykhtina, I. Strazhesko, D. Akasheva, A. Kruglikova, E. Plokhova,
O. Isaykina, O. Tkacheva, S. Boytsov
National Research Center for Preventive Medicine, Moscow, Russian
Federation
Objective: Large arteries stiffness is a feature of arterial aging and a predic-
tor of cardiovascular diseases. The length of telomere (TL) in leukocytes is
widely considered as a biomarker for cellular aging, cardiovascular aging
and cardiovascular diseases. High concentrations of urea is known to in-
crease oxidative stress. The aim of our study was to determine whether
the indicators of renal function are associated with TL and arterial stiffness,
evaluated by measuring aortic pulse wave velocity (PWV).Methods: The study group included 150 subjects free of known cardiovascu-
lar diseases, kidney diseases, anti-diabetes, antihypertensive and lipid
lowering medications. PWV was measured with the help of SphygmoCor
(AtCor Medical). Telomere length has been determined by quantitative poly-
merase chain reaction. Renal function was assessed by creatinine clearance
calculated with the MDRD formula . Microalbuminuria (MAU) and urea levels
were determined using routine laboratory methods.
Results: Pearson’s correlations are demonstrated in the table 1 and table 2.In conclusion, even physiological concentrations of plasma urea contribute
to cellular and vascular aging. TL may play a role in kidney function. The
relationship between TL and kidney repair and regeneration needs
increasing studies.
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A COMPARISON OF DIFFERENT METHODS TO DETERMINE AORTIC PULSE
WAVE VELOCITY IN ANEURYSMATIC AND CONTROL MICE
B. Trachet 1,2, R. Fraga-Silva 2, F. J. Londono-Hoyos 1, P. Segers 1,
N. Stergiopulos 2
1IBiTech-bioMMeda, Ghent University, Ghent, Belgium
2Laboratory of Hemodynamics and Cardiovascular Technology, EPFL,
Lausanne, Switzerland
Introduction: Accurate determination of aortic pulse wave velocity (PWV) in
mice is not straightforward, due to the high resolution needed in both time and
space. We compared different techniques in control and aneurysmatic mice.
Methods: NZ30 male, 18 weeks-old C57Bl/6 mice were included. NZ20 ani-
mals got implanted an osmotic pump delivering Angiotensin II, and were
injected anti-TGF-beta antibodies to provoke aneurysm formation. PWV was
determinedusing 4 differentmethods: (i) global foot-to-foot transit timebased
on ultrasound pulsed Doppler velocities (VisualSonics Vevo 2100) at the
ascending aorta and 4 cm distal to it (tape-measured); (ii) abdominal foot-
to-foot transit time based on 2 invasive pressure sensors placed exactly 2 cm
apart (Sciscense catheter), considered the gold standard; (iii) abdominal, in
vivo, invasive pressure-diameter (P-D) waveforms obtained via RF wall
tracking; (iv) abdominal, ex-vivo P-D curves measured at in vivo stretch using
an in-housemyograph. The latter were restricted to the in vivo measured pres-
sure range. P-D data were converted to PWV using the Bramwell-Hill equation
and groups were statistically compared via a paired student-test.
Results: 13 complete datasets were available for analysis. In the control an-
imals all in vivo methods yielded significantly different PWVs compared to
the gold standard (p<0.05), and none of the investigated methods were
found to correlate to each other. Moreover aneurysm presence was not
picked up by transit-time methods, while it resulted in a significant increase
in PWV (p<0.0001) in both P-D methods.
Abstracts 139Conclusions: PWV measurement in mice is not straightforward and results
should be interpreted carefully.P4.13
VITAMIN D SUPPLEMENTATION IMPROVES ENDOTHELIAL FUNCTION IN
TYPE 2 DIABETES e A RANDOMIZED CONTROLLED TRIAL
K. Angel 1, H. L. Gulseth 1, C. Wium 1, E. F. Eriksen 1,2, D. Atar 1,2,
K. Birkeland 1,2
1Oslo University Hospital, Oslo, Norway
2University of Oslo, Oslo, Norway
Background: Cardiovascular disease is prevalent in type 2 diabetes, and
both endothelial dysfunction and arterial stiffness may contribute in the
pathogenesis. Low levels of vitamin D are associated with both type 2 dia-
betes and cardiovascular disease.
Aim: To evaluate the effect of vitamin D supplementation on endothelial
function and arterial stiffness in subjects with type 2 diabetes and hypovita-
minosis D.
Methods: Sixty-two subjects with type 2 diabetes and serum 25-hydroxy-
vitamin D [25(OH)D] <50 nmol/L were included in this randomized
controlled trial (NCT 00992797). Thirty-three patients received vitamin D
(400 000 IU cholecalciferol) at baseline, whereas 29 patients received pla-
cebo. Endothelial function and arterial stiffness were measured at baseline
and after six months. Endothelial function was assessed as the reactive
hyperaemia index (RHI) using endothelial pulse amplitude testing (Endo-
PAT). Arterial stiffness was estimated as carotid-femoral pulse wave velocity
(cfPWV) and augmentation index (AIx) with the SphygmoCor device. Serum
25(OH)D was measured using the DiaSorin-RIA.
Results: Mean (SD) age in the treatment and placebo group were 57.5 (9.4)
and 57.8 (10.0) years, 51.5 % (nZ17) and 44.8 (nZ13) were females, and
diabetes duration was 11.4 (6.5) and 7.5 (5.7) years. Vitamin D supplemen-
tation significantly improved RHI and increased the 25(OH)D levels, but did
not change cfPWV and AIx (Table 1). In multivariable regression analysis,
change in RHI was significantly associated with change in 25(OH)D levels (b
[CI] Z 0.009 [0.001-0.017], PZ0.03).
Conclusion: Vitamin D supplementation improved endothelial function but
not arterial stiffness in subjects with type 2 diabetes.Table 1 Baseline values and change in endothelial function, arterial stiffness
represents the significance of between-group-comparisons for baseline values
Baseline
Treatment (nZ33) Control (nZ29)
RHI 1.7 (0.4) 1.7 (0.5)
cfPWV, m/s 10.18 (1.85) 9.84 (2.33)
AIx, % 20.0 (8.7) 20.0 (10.1)
25(OH)D, nmol/L 38.5 (9.1) 38.1 (8.5)P4.14
RENAL DENERVATION IMPROVES CENTRAL HEMODYNAMICS AND PULSE
PRESSURE AMPLIFICATION IN PATIENTS WITH TREATMENT RESISTANT
HYPERTENSION
C. Ott 1, A. Schmid 2, T. Ditting 1, R. Veelken 1, M. Uder 2,
R. E. Schmieder 1
1Department of Nephrology and Hypertension, University of Erlangen-
Nuremberg, Erlangen, Germany
2Department of Radiology, University of Erlangen-Nuremberg, Erlangen,
Germany
Background: Renal denervation (RDN) was shown to be effective in reducing
peripheral BP in treatment resistant hypertension. Accumulating data sug-
gest that central pressures may be a better predictor of cardiovascular
events and outcomes than the corresponding peripheral pressure. PP ampli-
fication is among others inversely related to stiffer arteries and peripheral
arterial resistance.
Methods: 57 patients with treatment resistant hypertension (office BP
140/90 mmHg, while on at least 3 antihypertensive agents, and diagnosis
confirmed by 24-h ABPM 130/80 mmHg) underwent catheter-based RDN us-
ing the Symplicity FlexTM catheter (Medtronic Inc., Palo Alto, CA). In addi-
tion, in our lab pulse wave analysis was assessed with the SphygmoCorTM
device (AtCor Medical, Australia) before and after 6 months of RDN. PP
amplification is determined as ratio of peripheral PP to central PP.
Results: Patients (5912 years) were treated with 6.01.3 antihypertensive
drugs on average. Peripheral as well as central systolic and diastolic BP were
reduced (all p<0.01) 6 months after RDN. In accordance, peripheral PP
(77.522 versus 71.523 mmHg, pZ0.008) and central PP (63.221 versus
56.722 mmHg, pZ0.001) were reduced 6 months after RDN. Consistently,
there was a significant improvement in PP amplification (1.250.2 versus
1.300.2, pZ0.012). Also central augmentation pressure (2012 versus
1613 mmHg, p<0.001) and cAIx@75 (2410 versus 2111 %, pZ0.005)
decreased 6 months after RDN. There was no change on heart rate (6311
versus 6410 bpm, pZ0.499).
Conclusion: Our data suggest that RDN might exert beneficial effects indi-
cated by an improvement of central PP beyond peripheral PP, and hence
PP amplification.
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EFFECT OF RENIN ANGIOTENSIN SYSTEM BLOCKADE ON SOLUBLE
KLOTHO, ARTERIAL STIFFNESS AND ALBUMINURIA IN PATIENTS WITH
TYPE 2 DIABETES AND SYSTOLIC HYPERTENSION
G. Maltese, G. Viberti, L. Gnudi, J. Karalliedde
King’s College London, London, United Kingdom
Background: Soluble Klotho is an anti-ageing phosphaturic protein associ-
ated with cardiovascular and renal protection. In-vitro and in-vivo studies
have demonstrated that rennin-angiotensin-system (RAS) blockade increases
soluble Klotho levels. The effect of RAS blockers on soluble Klotho in pa-
tients with diabetic-kidney-disease (DKD) is unknown.
Methods and measurements: Plasma soluble Klotho was measured in a sec-
ondary analysis of a randomised controlled clinical trial performed at a sin-
gle university centre. Seventy-six patients with Type-2 diabetes, and DKD
(all with albuminuria and serum creatinine <1.7mg/dl) were studied at
baseline and at 24-weeks (end of study), following randomisation to valsar-
tan/hydrochlorothiazide (nZ37) or amlodipine (nZ39) treatment. Aortic-
pulse wave velocity (Ao-PWV) by applanation tonometry and albuminuria
(from 3-timed urine collections) were also measured at baseline and 24-
weeks.
Results: Valsartan/hydrochlorothiazide treatment significantly increased
soluble Klotho meanstandard deviation, from 432.7179 to 506.4226.8and vitamin D from baseline to 6 months. Values are given as mean (SD). P
and changes after 6 months respectively.
Change
P Treatment (nZ33) Control (nZ29) P
0.74 0.21 (0.49) -0.03 (0.37) 0.04
0.54 -0.21 (0.92) -0.10 (0.64) 0.56
0.98 0.8 (5.0) 3.5 (8.4) 0.54
0.74 15.0 (11.0) 0.7 (16.0) <0.001
